By PDADCO payday loan
Written by Dentistry Today Wednesday, 14 November 2012 19:37
A team of National Institute of Dental and Craniofacial Research (NIDCR) scientists and colleagues answer in the affirmative in the journal Cancer Prevention Research. The scientists found in a range of standard HNSCC cell lines that metformin prevents their progression, but the compound may do so independently of the LKB1-AMPK. They then showed in mice that metformin acts primarily on the basal proliferating layer of premaliganant lesions, significantly reducing their size and number. The authors concluded, “Collectively, our data underscore the potential clinical use of metformin as a targeted chemopreventive agent in the control of HNSCC development and progression.”
(Source: NIDCR, Science News in Brief, accessed August 17, 2012; Cancer Prevention Research, April 2012, Volume 5, Number 4, pages 562 to 573)

